narcolepsy with cataplexy: Narcolepsy with cataplexy is a sleep disorder characterized by excessive day-time sleepiness associated with uncontrollable sleep urges and cataplexy (loss of muscle tone often triggered by pleasant emotions).
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
272 |
4. Check minimum number of eventsNone |
272 |
5. Include endpointsNone |
272 |
6. Filter based on genotype QC (FinnGen only) |
263 |
Control definitions (FinnGen only)
- Control exclude
- G6_EPIPAROX
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G47
- Name in latin
- Narcolepsia
Similar endpoints
↥List of similar endpoints to
Narcolepsy and cataplexy
based on the number of shared cases.
Similar with more cases:
- Sleep disorders (combined)
- Autoimmune diseases
- Episodal and paroxysmal disorders
- Used for control exclusion in common control thyroid runs
- Neurological diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1805 | 929 | 870 |
| Only index persons | 1664 | 880 | 784 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 32.44 | 28.45 | 36.61 |
| Only index persons | 30.04 | 27.56 | 32.81 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 263 | 154 | 109 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.05 |
| Median age at first event (years) | 35.99 | 32.13 | 41.45 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 272
- Matched controls
- 2720
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G47.4
ICD-10 Finland
Narcolepsy and cataplexy
+∞
307.7
247
*
G47.3
ICD-10 Finland
Sleep apnoea
44.2
180.8
119
47
N06BA07
ATC
modafinil; oral
+∞
126.1
111
*
214
Kela drug reimbursment
Severe and chronic narcolepsy
+∞
104.0
93
*
N06BA04
ATC
methylphenidate; oral
17.7
98.9
94
79
TAB00
NOMESCO Finland
Lumbar puncture
23.0
95.6
76
45
282
Kela drug reimbursment
Sodium oxybat
+∞
86.1
78
*
G47.9
ICD-10 Finland
Sleep disorder, unspecified
29.7
68.1
47
19
N07XX04
ATC
sodium oxybate; oral
+∞
59.6
55
*
R5140
NOMESCO Finland
Monitoring the use of the aid
15.3
45.3
42
32
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
9.8
42.1
54
67
N06AX16
ATC
venlafaxine; oral
6.4
40.3
83
174
G47.1
ICD-10 Finland
Disorders of excessive somnolence [hypersomnias]
+∞
38.5
36
*
3035, ,
Kela drug reimbursment
+∞
30.8
29
*
N04BD01
ATC
selegiline; oral
55.9
25.8
30
6
R06.5
ICD-10 Finland
Mouth breathing
7.5
25.4
39
59
3471A
ICD-9 Finland
Cataplexy and narcolepsy[NARCOLEPSIA]
+∞
23.3
22
*
N07XX11
ATC
pitolisant; oral
+∞
23.3
22
*
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
7.3
22.8
36
56
N06AA04
ATC
clomipramine; systemic
38.8
22.5
28
8
R53
ICD-10 Finland
Malaise and fatigue
3.7
22.1
94
337
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.6
21.2
44
90
N06BA14
ATC
solriamfetol; oral
+∞
21.1
20
*
N04BC05
ATC
pramipexole; oral
6.2
18.2
33
59
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
6.0
17.6
33
61
N06AX18
ATC
reboxetine; oral
29.7
16.8
22
8
N06AB04
ATC
citalopram; systemic
3.6
16.5
66
223
R03CA02
ATC
ephedrine; oral
+∞
15.8
15
*
34700
ICD-8 Finland
Other disease of brain, Cataplexy and narcolepsy
+∞
15.8
15
*
R40.0
ICD-10 Finland
Somnolence
45.1
14.3
17
*
Z01.8
ICD-10 Finland
Other specified special examinations
3.0
12.9
70
282
G44.2
ICD-10 Finland
Tension-type headache
4.2
12.6
36
95
3472A
ICD-9 Finland
Cataplexy and narcolepsy[OBSTRUKTIIVINEN UNIAPNEA]
+∞
12.6
12
*
E66.01
ICD-10 Finland
Obesity due to excess calories
4.0
12.6
38
105
XA800
NOMESCO Finland
Neuropsychological investigation
5.9
12.3
23
42
A02BA02
ATC
ranitidine; systemic
3.4
12.3
50
169
Z2445
NOMESCO Finland
Psychologist
4.9
12.2
28
62
E66.00
ICD-10 Finland
Metabolic syndrome
5.9
11.8
22
40
WX722
NOMESCO Finland
PEEP
21.1
11.3
16
8
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.3
10.9
47
164
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
5.4
10.7
22
44
XA420
NOMESCO Finland
Extensive sleep examination
114.2
10.5
11
*
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
16.9
10.5
16
10
E66.8
ICD-10 Finland
Other obesity
5.2
10.5
22
45
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.6
10.3
74
342
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
4.2
10.2
29
76
A04
ICPC
Weakness/tiredness general
2.9
10.2
54
213
N03AX12
ATC
[U] gabapentin; oral
3.1
10.0
46
167
J45.9
ICD-10 Finland
Asthma, unspecified
2.8
10.0
58
240
N03AX16
ATC
[U] pregabalin
2.8
10.0
60
253
UJF32
NOMESCO Finland
Coloscopy
2.7
9.9
65
286
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
27.2
9.9
13
5
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.8
9.8
56
229
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.3
9.5
108
609
R42
ICD-10 Finland
Dizziness and giddiness
2.8
9.5
54
220
S97
ICPC
Chronic ulcer skin
5.2
9.5
20
41
R03AC02
ATC
salbutamol; inhalant
2.2
9.5
160
1061
WX780
NOMESCO Finland
Remote monitoring CPAP
+∞
9.4
9
*
H02AB06
ATC
prednisolone; systemic
2.2
9.3
124
746
A02BC03
ATC
lansoprazole; oral
2.5
9.3
69
322
G25.8
ICD-10 Finland
Other specified extrapyramidal and movement disorders
10.6
9.2
17
17
R03BB04
ATC
tiotropium bromide; inhalant
4.2
9.1
25
64
N06AX12
ATC
bupropion; oral
3.5
9.0
33
104
R51.80
ICD-10 Finland
Headache
2.7
8.9
53
221
P06
ICPC
Sleep disturbance
3.1
8.8
39
138
G43.0
ICD-10 Finland
Migraine without aura [common migraine]
4.7
8.5
20
45
T90
ICPC
Diabetes non-insulin dependent
2.7
8.5
53
227
N06AA09
ATC
amitriptyline; systemic
4.1
8.4
24
63
G47.2
ICD-10 Finland
Disorders of the sleep-wake schedule
+∞
8.4
8
*
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
+∞
8.4
8
*
N03AX09
ATC
lamotrigine; oral
4.5
8.4
21
50
N03AE01
ATC
clonazepam; systemic
4.8
8.3
19
42
AA1AD
NOMESCO Finland
CT of head and brain
2.6
8.0
52
226
G43.1
ICD-10 Finland
Migraine with aura [classical migraine]
4.7
8.0
19
43
285
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
4.9
8.0
18
39
R55
ICD-10 Finland
Syncope and collapse
3.3
8.0
31
101
N06AB03
ATC
fluoxetine; oral
3.0
7.9
37
135
M79.6
ICD-10 Finland
Pain in limb
2.1
7.9
106
631
R07.4
ICD-10 Finland
Chest pain, unspecified
2.3
7.7
67
333
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.7
7.7
44
179
G45.9
ICD-10 Finland
Transient cerebral ischaemic attack, unspecified
19.0
7.7
11
6
XG466
NOMESCO Finland
Sleep oxymetry
12.3
7.7
13
11
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.6
7.4
25
74
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
3.2
7.3
30
101
WX723
NOMESCO Finland
CPAP therapy
+∞
7.3
7
*
U04
ICPC
Incontinence urine
6.3
7.2
18
30
N02CC01
ATC
sumatriptan; nasal, systemic, rectal
2.6
7.2
44
186
L28
ICPC
Limited function/disability (L)
2.7
7.0
40
163
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.3
7.0
27
88
N03AG01
ATC
valproic acid; systemic, rectal
4.3
6.9
18
44
N06AB05
ATC
paroxetine; oral
3.8
6.9
21
58
215
Kela drug reimbursment
Diabetes, non-insulin-treated
2.4
6.9
55
263
103
Kela drug reimbursment
Diabetes, insulin-treated
2.3
6.9
59
291
H02AB04
ATC
methylprednisolone; systemic
2.7
6.8
39
159
G43.9
ICD-10 Finland
Migraine, unspecified
4.2
6.7
18
45
XQ800
NOMESCO Finland
Prick test
3.2
6.5
26
86
A10BA02
ATC
metformin; oral
2.2
6.5
63
326
N06AX21
ATC
duloxetine; oral
2.9
6.5
31
114
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
2.9
6.5
32
120
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.9
6.4
32
121
B01AB05
ATC
enoxaparin; parenteral
2.1
6.4
69
373
N02AX02
ATC
tramadol; systemic, rectal
2.0
6.3
93
565
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
3.9
6.2
18
48
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.3
6.2
50
240
F45.4
ICD-10 Finland
Persistent somatoform pain disorder
12.9
6.1
10
8
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
2.3
6.1
54
269
M54.4
ICD-10 Finland
Lumbago with sciatica
2.4
6.1
46
214
SPAT1262
SPAT
Handing over of treatment supplies
2.5
6.1
41
181
R60.0
ICD-10 Finland
Localized oedema
2.9
6.0
28
102
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
135
806
2.34
10.70
4.9
5.8
1.21
1.21
mmol/l
0.32
110
691
123
710
2.34
10.49
4.6
5.0
1.21
1.21
mmol/l
0.08
111
657
138
904
2.07
7.95
5.4
5.9
9.47
11.21
umol/l
2.38
132
858
57
261
2.50
7.90
1.9
1.6
1360.50
1153.96
nmol/l
0.91
43
211
153
1048
2.05
7.72
4.5
4.0
6.82
6.50
mmol/l
1.02
144
945
112
689
2.06
7.56
4.9
4.3
36.80
36.56
g/l
0.19
107
658
26
80
3.49
7.32
4.0
4.0
1.61
2.35
mmol/l
0.54
21
57
14
16
9.16
7.14
1.1
1.1
—
—
—
0
0
14
17
8.61
6.91
1.1
1.2
—
—
—
0
0
43
191
2.49
6.30
9.5
5.0
—
—
—
0
0
14
21
6.97
6.12
1.1
1.1
—
—
—
0
0
68
378
2.07
5.83
3.5
2.7
1085.14
1122.14
ng/l
0.02
61
310
158
1163
1.86
5.78
9.2
8.7
4.03
4.06
e9/l
0.05
139
1019
76
446
1.98
5.58
4.9
3.6
5.90
8.76
mg/mmol
0.62
47
277
13
21
6.44
5.45
1.1
1.1
—
—
—
0
0
99
640
1.86
5.41
2.4
1.7
106.60
93.89
pmol/l
1.51
51
330
185
1448
1.87
5.38
7.8
6.6
76.08
77.94
u/l
0.23
176
1357
91
575
1.88
5.33
4.5
3.1
19.57
48.64
ng/l
2.28
56
338
86
540
1.87
5.11
2.9
2.4
52.30
64.17
u/l
0.74
79
503
105
708
1.79
4.91
20.5
9.4
1.18
1.20
inr
0.09
29
234
27
110
2.61
4.72
1.7
1.5
—
—
—
0
0
64
374
1.93
4.69
1.5
1.4
21.63
19.61
nmol/l
0.46
57
321
182
1448
1.78
4.68
4.4
3.5
11.27
9.83
mm/h
0.67
165
1339
68
406
1.90
4.67
1.9
1.6
1.18
1.28
mg/l
0.12
47
300
86
565
1.76
4.30
2.8
3.0
2.33
2.36
mmol/l
1.66
76
513
131
973
1.67
4.15
3.8
2.5
70.24
96.60
ug/l
1.68
123
912
14
42
3.46
4.10
2.4
2.1
—
—
—
0
0
43
229
2.04
4.07
1.4
1.7
—
—
—
0
0
57
337
1.87
4.00
1.5
1.7
468.67
429.29
pmol/l
0.73
46
301
130
973
1.64
3.93
4.4
2.9
0.00
0.01
estimate
0.50
25
195
83
554
1.72
3.87
1.5
1.6
—
—
—
0
0
80
531
1.72
3.80
1.4
1.3
1.08
2.24
u/ml
0.70
20
143
192
1604
1.67
3.61
4.3
3.6
14.37
14.61
pmol/l
0.74
180
1461
70
454
1.73
3.60
4.2
2.9
1.02
1.02
kg/l
0.12
12
56
71
465
1.71
3.52
2.5
1.9
2.75
2.82
mg/l
0.14
58
397
6
6
10.19
3.51
1.2
1.0
—
—
—
0
0
221
1929
1.78
3.40
4.7
3.5
5.94
5.69
mmol/l
1.91
202
1778
7
10
7.15
3.38
1.1
1.6
1.91
1.73
mmol/l
—
7
10
76
514
1.66
3.32
4.5
3.1
0.00
0.00
estimate
-0.00
25
177
32
166
2.05
3.26
1.4
1.6
—
—
—
0
0
32
168
2.03
3.16
1.4
1.6
—
—
—
0
0
127
986
1.54
3.06
4.5
3.0
0.00
0.00
estimate
-0.00
25
175
47
285
1.78
3.02
4.8
3.0
91.21
192.53
ng/l
0.74
29
196
219
1929
1.69
2.99
5.3
4.1
1.65
1.82
mu/l
2.24
205
1783
125
972
1.53
2.97
6.2
4.1
0.00
0.00
estimate
-0.00
25
185
239
2171
1.83
2.74
16.7
9.9
19.34
22.66
mg/l
0.95
204
1593
26
135
2.02
2.66
3.4
3.1
1.91
1.90
mmol/l
0.00
19
99
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
7
7.25
2.56
1.0
1.3
—
—
—
0
0
214
1905
1.58
2.45
14.3
9.5
89.69
90.00
ml/min/173m2
0.06
184
1523
103
795
1.48
2.42
2.6
2.2
73.23
74.46
nmol/l
0.19
96
724
30
170
1.86
2.40
3.4
7.4
0.72
0.91
mmol/l
0.15
22
136
5
8
6.34
2.38
1.0
1.0
—
—
—
0
0
99
765
1.46
2.29
4.6
3.0
—
—
—
0
0
38
239
1.69
2.16
2.3
1.8
—
—
—
0
0
45
297
1.62
2.13
1.3
1.2
23.58
12.97
u/ml
0.26
17
121
8
25
3.26
2.11
1.4
2.4
22.56
24.58
nmol/l
—
8
25
18
91
2.05
2.00
4.1
6.0
24.46
24.80
mmol/l
0.22
18
91
35
225
1.64
1.85
3.7
2.1
25.88
25.40
%
0.07
29
201
43
291
1.57
1.85
2.6
1.8
—
—
—
0
0
57
411
1.49
1.84
3.9
2.5
331.57
6279.01
umol/l
1.77
49
374
79
608
1.42
1.82
4.7
2.8
—
—
—
0
0
27
163
1.73
1.79
1.7
2.4
6774.79
4459.28
u/l
—
7
69
114
940
1.37
1.73
3.3
2.4
—
—
—
0
0
32
207
1.62
1.66
5.3
3.2
34.60
31.71
%
0.64
20
136
20
113
1.83
1.65
4.5
3.4
83.14
70.43
ng/l
0.32
14
102
8
32
2.54
1.61
1.0
1.2
—
128.86
—
0
7
10
43
2.38
1.60
2.0
1.1
—
—
—
0
0
194
1752
1.37
1.57
7.1
4.5
39.97
38.40
mmol/mol
1.28
179
1656
5
15
3.37
1.53
1.4
3.1
12.00
11.73
%
—
5
15
43
305
1.49
1.51
1.3
1.2
9.04
30.61
iu/ml
2.68
16
102
6
23
2.64
1.37
1.0
1.6
15286.17
4932.06
e6/l
—
6
17
27
178
1.57
1.32
5.6
3.7
215.11
231.14
u/l
0.75
27
173
8
37
2.20
1.22
3.0
3.5
53.50
57.35
%
—
8
37
5
19
2.66
1.22
1.2
1.1
—
—
—
0
0
8
39
2.08
1.16
1.3
1.2
—
—
—
0
0
15
243
0.59
1.15
1.5
1.5
—
—
—
0
0
11
58
1.93
1.13
1.5
2.1
—
—
—
0
0
7
138
0.49
1.13
1.4
1.5
—
—
—
0
0
10
51
2.00
1.12
1.1
1.2
—
—
—
0
0
160
1442
1.27
1.11
3.6
2.6
46.28
38.75
u/l
0.72
152
1366
259
2506
1.70
1.06
25.1
15.0
40.61
40.43
%
0.19
247
2379
12
67
1.83
1.06
1.2
1.6
—
—
—
0
0
9
46
1.99
1.04
2.1
1.6
—
—
—
0
0
57
456
1.32
1.02
2.4
2.1
—
—
—
0
0
7
35
2.03
1.00
1.4
1.2
—
—
—
0
0
9
49
1.86
0.99
1.2
1.3
—
2.53
—
0
10
5
23
2.20
0.98
1.4
1.3
—
—
—
0
0
28
200
1.45
0.98
4.0
2.6
4.60
8.96
umol/l
1.48
22
172
10
54
1.88
0.98
1.1
1.1
—
—
—
0
0
7
36
1.97
0.97
1.3
1.9
—
—
—
0
0
24
168
1.47
0.93
1.2
1.3
22.67
190.98
iu/ml
—
9
67
9
52
1.76
0.93
1.0
1.8
—
—
—
0
0
7
127
0.54
0.91
1.4
1.4
—
—
—
0
0
7
127
0.54
0.91
1.4
1.4
—
—
—
0
0
7
127
0.54
0.91
1.4
1.4
—
—
—
0
0
7
127
0.54
0.91
1.4
1.4
—
—
—
0
0
61
501
1.28
0.90
2.5
2.3
—
—
—
0
0
56
455
1.29
0.90
2.3
2.1
—
—
—
0
0
16
103
1.59
0.89
1.4
1.4
—
—
—
0
0
10
56
1.82
0.89
1.1
1.9
—
—
—
0
0
6
32
1.89
0.82
1.3
1.4
—
—
—
0
0
56
462
1.27
0.80
1.4
1.6
1.49
1.31
mmol/l
0.93
50
406
7
38
1.86
0.74
2.9
2.6
135.71
130.33
g/l
—
7
30
5
25
2.02
0.73
1.8
1.4
—
—
—
0
0
9
58
1.57
0.70
1.1
1.3
—
—
—
0
0
9
58
1.57
0.70
1.6
1.5
—
—
—
0
0
23
171
1.38
0.68
1.7
2.3
31.78
30.55
u/l
0.10
18
152
14
95
1.50
0.65
3.8
2.6
127.71
176.83
ng/l
0.33
14
83
183
1727
1.18
0.62
3.1
3.7
—
—
—
0
0
13
88
1.50
0.62
1.8
1.7
6.63
12.67
u/l
1.68
13
70
50
426
1.21
0.55
1.5
1.4
—
—
—
0
0
9
61
1.49
0.54
2.2
2.1
3.98
3.54
g/l
—
9
56
33
270
1.25
0.53
4.0
2.5
0.33
1.22
e6/l
3.24
18
155
7
47
1.50
0.48
1.6
1.4
—
—
—
0
0
7
47
1.50
0.48
1.6
1.4
—
—
—
0
0
12
85
1.43
0.47
1.3
1.3
—
—
—
0
0
20
251
0.78
0.44
1.2
1.5
—
—
—
0
0
16
122
1.33
0.43
2.1
2.6
62.88
76.69
ml/min/173m2
—
8
55
5
31
1.62
0.43
1.0
1.3
—
—
—
0
0
5
33
1.52
0.41
1.4
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
2.7
—
77.42
—
0
16
0
16
0.00
0.41
0.0
1.9
—
—
—
0
0
0
18
0.00
0.40
0.0
1.6
—
—
—
0
0
5
35
1.44
0.39
1.8
1.4
—
—
—
0
0
6
41
1.47
0.36
1.7
1.3
—
—
—
0
0
6
42
1.44
0.36
1.7
1.4
—
—
—
0
0
200
1936
1.12
0.34
4.3
3.1
1.37
1.21
mmol/l
1.51
177
1806
6
45
1.34
0.34
1.0
1.2
—
—
—
0
0
208
2019
1.13
0.34
4.6
3.4
1.39
1.47
mmol/l
2.02
187
1884
209
2031
1.13
0.32
4.7
3.5
4.48
4.65
mmol/l
1.66
193
1907
30
260
1.17
0.30
4.7
2.7
0.85
3.16
e6/l
2.87
15
146
53
481
1.13
0.29
4.6
2.7
0.15
0.39
e6/l
1.90
42
352
13
106
1.24
0.23
1.8
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
39
355
1.12
0.21
4.2
4.4
20.61
22.40
%
0.27
16
170
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
8
70
1.15
0.16
2.1
1.6
—
0.00
—
0
17
8
71
1.13
0.16
1.1
1.1
—
—
—
0
0
8
71
1.13
0.16
1.1
1.1
—
—
—
0
0
15
172
0.86
0.16
1.4
1.3
—
—
—
0
0
11
93
1.19
0.14
4.6
9.2
94.85
94.93
%
0.05
11
93
12
139
0.86
0.14
1.2
1.0
—
—
—
0
0
209
2059
1.07
0.14
4.8
3.7
2.70
2.79
mmol/l
0.76
191
1916
7
64
1.10
0.08
1.1
1.1
—
—
—
0
0
8
74
1.08
0.07
1.1
1.5
—
—
—
0
0
11
122
0.90
0.07
1.4
1.5
—
—
—
0
0
13
120
1.09
0.05
1.6
2.1
—
—
—
0
0
27
261
1.04
0.02
3.4
3.0
0.50
0.81
ug/l
1.96
15
162
11
109
1.01
0.00
2.5
1.5
—
—
—
0
0
17
175
0.97
0.00
4.1
2.7
—
—
—
0
0
5
58
0.86
0.00
3.2
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
8
87
0.92
-0.00
1.3
1.4
—
—
—
0
0
9
98
0.92
-0.00
1.3
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.6
—
—
—
0
0
7
76
0.92
-0.00
1.9
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
9.27
—
0
5
0
8
0.00
-0.00
0.0
7.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_NARCOCATA and mortality.
Females
No dataMales
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_NARCOCATA | 1.095 [0.82, 1.46] | 0.53 |
| Birth year | 0.984 [0.97, 0.99] | 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 52 out of 635 males with G6_NARCOCATA died.
Mortality risk
Mortality risk for people of age
years, who have G6_NARCOCATA.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | 0.215% |
| 5 | No data | 1.126% |
| 10 | No data | 2.798% |
| 15 | No data | 5.169% |
| 20 | No data | 9.036% |
Relationships between endpoints
↥Index endpoint: G6_NARCOCATA – Narcolepsy and cataplexy
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data